Formycon AG (ETR:FYB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 498.81M |
| Revenue (ttm) | 69.67M |
| Net Income (ttm) | -125.67M |
| Shares Out | 17.66M |
| EPS (ttm) | -7.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,007 |
| Average Volume | 33,342 |
| Open | 27.00 |
| Previous Close | 28.25 |
| Day's Range | 27.00 - 29.75 |
| 52-Week Range | 19.18 - 64.40 |
| Beta | 0.58 |
| RSI | 70.03 |
| Earnings Date | Aug 13, 2025 |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]
Financial Performance
Financial StatementsNews
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany
EQS-News: Formycon AG / Key word(s): Miscellaneous Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany 26.0...
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada
EQS-News: Formycon AG / Key word(s): Miscellaneous U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb...
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Formycon AG / Key word(s): Issue of Debt/Bond Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period 24.06.2025 / 19:50 CET/CEST The issuer is solely respons...
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon AG / Key word(s): Issue of Debt/Bond Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse 20.06.2025 / 09:00 CET/CEST The issuer is solely responsible f...
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Formycon AG / Key word(s): AGM/EGM/Miscellaneous Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities 18.06.2025 / 16:43 CET/CEST The issuer i...
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG / Key word(s): Issue of Debt/Bond Formycon AG: Subscription period for 2025/2029 corporate bond has started 18.06.2025 / 06:25 CET/CEST The issuer is solely responsible for the c...
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon AG / Key word(s): Bond Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets 17.06.2025 / 08:01 CET/CEST The issuer is sole...
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Ad-hoc: Formycon AG / Key word(s): Bond/Issue of Debt Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth 17...
EQS-News: Lucentis biosimilar FYB201/Ranivisio (ranibizumab) approved in Brazil
EQS-News: Formycon AG / Key word(s): Regulatory Approval Lucentis biosimilar FYB201/Ranivisio (ranibizumab) approved in Brazil 05.06.2025 / 06:30 CET/CEST The issuer is solely responsible for the cont...
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon AG / Key word(s): Market Launch Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CEST...
Formycon's Q1 2025: Stellar Performance & Financial Triumph
Formycon AG's Q1 2025 showcases strategic prowess with key approvals, partnerships, and financial strength, setting a promising tone for the year. Jetzt den vollständigen Artikel lesen
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon AG / Key word(s): Quarter Results Formycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CEST The issuer is solely re...
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences 07....
EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of quarterly r...
Formycon's 2024: Financial Success & Market Growth
Formycon AG has surpassed expectations in 2024, achieving significant financial and operational milestones, and setting a promising course for future growth. Jetzt den vollständigen Artikel lesen
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon AG / Key word(s): Annual Report/Annual Results Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market posit...
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Formycon AG / Key word(s): Conference/Annual Report Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor confer...
EQS-News: FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the United States and the European Union
EQS-News: Formycon AG / Key word(s): Product Launch FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the United States and the European Union 03.03.2025 / 14:00 CET/CEST The issu...
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE
EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE 25.02.2025 / 06...
EQS-DD: Formycon AG: Dr. Andreas Seidl, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 21.02.2025 / 15:59 CET/CEST The issuer is solely responsi...
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
EQS-News: Formycon AG / Key word(s): Scientific publication Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CEST The issuer is so...
Formycon AG: Biosimilar Updates & Conference Call Invite
Formycon AG halts Phase III trial for FYB206, saving investments and reshaping strategies amid U.S. biosimilar market shifts. Jetzt den vollständigen Artikel lesen
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27 CET/CEST The issuer is...
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
EQS-Ad-hoc: Formycon AG / Key word(s): Study/Statement Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 17-...
EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea biosimilar FYB203/AHZANTIVE in the Asia-Pacific Region
EQS-News: Formycon AG / Key word(s): Agreement Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea biosimilar FYB203/AHZANTIVE in the Asia-Pacific Region 05.02...